| | L.E.K.’s Looking Ahead 2022 series of Executive Insights looks at how accelerated innovation has brought both unprecedented achievement and enduring challenges for companies throughout the healthcare ecosystem. Click to read more. |
|---|
'Science doesn't care' about markets: ARCH raises nearly $3B amid tough times for biotechs Gilead, Sanofi, GSK and more to pay for employees' abortion-related travel costs after Roe ruling Deloitte: Health inequities cost industry $320B per year, signal unsustainable crisis Fierce Next Gen: Biopharma begins to hand AI the keys to the research car Fierce NextGen: Despite another key trial failure, Alzheimer's therapy developers find reason for optimism Fujifilm plots $1.6B expansion at CDMO sites in Denmark and Texas, adding 450 jobs Kaufman Hall: Revenue and volume bump not enough to turn around margins for hospitals in May Philips attributes foam breakdowns in recalled CPAP ventilators to ozone-based cleaners 'Science at its hardest': FDA panel recommends incorporating omicron variant into future COVID boosters Merck launches healthcare startup incubator for AI developers Judge rules Apple Watch infringed AliveCor's ECG patent, setting up potential U.S. import ban Steeling itself for undruggable challenges, Astellas inks $180M deal to bolster mitochondria R&D unit US secures more Lilly COVID-19 antibodies for $275M, but with pandemic funding uncertain this may be a swan song Visby Medical’s VC round swells to $135M to add new tests to handheld PCR platform Featured Story | By Max Bayer ARCH Venture Partners has raised nearly $3 billion in a new venture fund, a glimmer of hope as biotechs large and small lick their wounds amid a market downturn that's lasted more than a year. The early investment firm was able to secure roughly a billion more dollars this time around compared to its previous fund. read more |
| |
|---|
|
Top Stories By Zoey Becker After the Supreme Court overturned the landmark Roe v. Wade ruling, companies across industries are stepping in to support employees who need to cross state lines for legal abortions. read more By Cameron Evans Inequities in the U.S. health system cost approximately $320 billion annually and could surpass $1 trillion in annual spending by 2040 if left unaddressed, according to a new analysis. read more By Conor Hale After years of harnessing AI's promise, the biopharma industry has recently begun to prove that artificial-intelligence-designed molecules can leapfrog their traditionally developed counterparts on their way toward human testing. read more By Annalee Armstrong As Genentech’s Greg Rippon, M.D., detailed his company’s failed Alzheimer’s disease study, his fellow panelists nodded solemnly. They’d all been there before. read more By Zoey Becker Fujifilm is expanding—again. This time, the Japanese company revealed plans to invest $1.6 billion to enhance its sites in Hillerød, Denmark, and Texas, creating 450 new jobs. read more By Robert King Slight increases in patient volumes and operating revenue were not enough for hospitals and health systems to overcome lingering expenses for labor and other areas, a Kaufman Hall report finds. read more By Andrea Park Over a year into its recall of more than 5 million respiratory devices distributed around the world, Philips this week reported the results of its testing on the polyester-based polyurethane foam at the center of the Class I recall. read more By Max Bayer FDA advisers voted 19-2 on Tuesday to recommend incorporating the omicron variant into future vaccine compositions. What exactly those compositions look like will be left to the FDA. read more By Conor Hale Merck has begun taking applications for a new biotech accelerator program and is on the hunt for startups offering a special focus on artificial intelligence and machine learning. read more By Heather Landi An administrative judge at the International Trade Commission sided with AliveCor in its case against Apple, ruling that the tech giant has infringed on the company's patented electrocardiogram technology. read more By Nick Paul Taylor Astellas has ventured off the beaten path for its latest R&D deal, heading to Pittsburgh to partner with low-profile Generian on the discovery of small molecules against undruggable targets. The pact pairs Generian with Mitobridge, an Astellas unit focused on compounds that target mitochondrial function. read more By Kevin Dunleavy Eli Lilly revealed an agreement with the U.S. to provide 150,000 doses of bebtelovimab for $275 million. Based on current demand, the supply should carry the U.S. through to the end of August. But it may be the last shipment of the antibodies to the government if Congress doesn't approve more funding for the pandemic. read more By Andrea Park Even after gobbling up an overstuffed funding round earlier this year, Visby Medical seems to have saved room for dessert. The cherry on top of that $100 million megaround is an extra dollop of venture capital that brings its final total to more than $135 million. read more |
